Department of Otolaryngology, Head and Neck Oncology, Medical University of Lodz, University Clinical Hospital Norbert Barlicki in Lodz, Poland.
Otolaryngol Pol. 2021 Apr 20;75(4):7-13. doi: 10.5604/01.3001.0014.7889.
<b>Introduction:</b> Tumors of large salivary glands constitute about 2-3% of all head and neck tumors. Their incidence is statistically greater in males than in females, with the first symptoms usually appearing between the 4th and 7th decade of life. <br/><b>Aim:</b> The aim of the study was to assess the usefulness of the new classification proposed by European Salivary Gland Society (ESGS) in comparison with the divisions of procedures previously valid in the literature, making a retrospective analysis of patients operated on due to benign tumors of large salivary glands in the Department of Otolaryngology, Head and Neck Oncology of the Medical University of Lodz in 2012-2020. <br/><b>Material and methods:</b> The retrospective examination was based on the material consisting of: surgical protocols, histopathological results, imaging results and clinical observations. The material includes 283 patients (141 women and 142 men): 249 patients with parotid gland tumor and 34 patients with submandibular gland tumor. The most common histopathological diagnosis was pleomorphic adenoma, which was found in 105 patients (42.17%) and adenolymphoma diagnosed in 94 patients (37.75%). <br/><b>Results:</b> The most common type of surgery was superficial parotidectomy including total superficial parotidectomy in 86 patients (34.54%) and partial superficial parotidectomy in 49 cases (19.68%). Then, according to the frequency of surgery, extracapsular tumor dissection (ECD) was performed (91 patients - 36.55%). According to the ESGS classification, in most cases parotidectomy I, II (37.34% of all parotidectomies) and parotidectomy II (28.49%) were performed. In case of ECD, all tumors were located at level II. <br/><b>Conclusions:</b> In summary, the new classification is aimed at unifying, but also simplifying the current nomenclature, reducing the existing nomenclature errors. Determination of the exact location and extent of the tumor within the parotid gland facilitates postoperative monitoring of patients by ENT doctors and those of other specialties.
<b>引言：</b> 大涎腺肿瘤约占所有头颈部肿瘤的 2-3%。其发病率在男性中高于女性，首发症状通常出现在 40 至 70 岁之间。 <br/><b>目的：</b> 本研究旨在评估欧洲涎腺学会（ESGS）提出的新分类法与文献中先前有效的手术分类法的有效性，对 2012 年至 2020 年在罗兹医科大学耳鼻喉头颈肿瘤科因大涎腺良性肿瘤接受手术的患者进行回顾性分析。 <br/><b>材料与方法：</b> 回顾性检查基于以下材料：手术方案、组织病理学结果、影像学结果和临床观察。该材料包括 283 名患者（141 名女性和 142 名男性）：249 名患者患有腮腺肿瘤，34 名患者患有颌下腺肿瘤。最常见的组织病理学诊断是多形性腺瘤，105 名患者（42.17%）和 94 名患者（37.75%）被诊断为腺淋巴瘤。 <br/><b>结果：</b> 最常见的手术类型是腮腺浅叶切除术，包括 86 例（34.54%）全腮腺浅叶切除术和 49 例（19.68%）部分腮腺浅叶切除术。然后，根据手术频率，进行囊外肿瘤切除术（ECD）（91 例，36.55%）。根据 ESGS 分类，大多数情况下行 I 型（37.34%的腮腺切除术）和 II 型（28.49%的腮腺切除术）腮腺切除术。在 ECD 的情况下，所有肿瘤均位于 II 级。 <br/><b>结论：</b> 总之，新分类旨在统一，同时简化当前命名法，减少现有命名法错误。确定肿瘤在腮腺内的确切位置和范围有助于耳鼻喉科医生和其他专业医生对患者进行术后监测。
